SparingVision raises €75m for eye disease gene therapies
pharmaphorum
SEPTEMBER 14, 2022
SparingVision has raised €75 million in second-round funding that will be used to fund clinical trials of gene therapies for ocular diseases retinitis pigmentosa (RP) and dry age-related macular degeneration (AMD). The current schedule is for trials to start in 2024, with first safety and efficacy data coming a year later.
Let's personalize your content